Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid

Pediatric Pulmonology

Volumn 46, Issue 11, 2011, Pages 1093-1097

  Lu, Aizhen ^a   Wang, Libo ^a   Zhang, Xiaobo ^a   Zhang, Mingzhi ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

children; ciprofloxacin; glucocorticoid; refractory M. pneumoniae pneumonia

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISONE; RNA 23S;

ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GENE MUTATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MYCOPLASMA PNEUMONIA; NASOPHARYNX; PLEURA EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THORAX RADIOGRAPHY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; MUTATION; MYCOPLASMA PNEUMONIAE; NASOPHARYNX; PLEURAL EFFUSION; PNEUMONIA, MYCOPLASMA; RNA, RIBOSOMAL, 23S; TREATMENT OUTCOME;

EID: 80055002140     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21481     Document Type: Article

References (18)

1. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T,. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008; 57: 223-228.
2. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M,. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010; 67: 355-358.
3. Dumke R, von Baum H, Lück PC, Jacobs E,. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010; 16: 613-616.
4. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM,. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008; 52: 3542-3549.
5. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K,. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother 2005; 49: 2302-2306. (Pubitemid 40734458)
6. Gendrel D, Chalumeau M, Moulin F, Raymond J,. Fluoroquinolones in paediatrics: a risk for the patient or for the community ? Lancet Infect Dis 2003; 3: 537-546. (Pubitemid 37064532)
7. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M, Tsang KW,. High dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168: 1449-1456. (Pubitemid 38037328)
8. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, Lee BC,. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006; 41: 263-268.
9. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, Chen X, Ma S, Hou A, Li G, Shi D,. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009; 53: 2158-2159.
10. Rollins S, Colby T, Clayton F,. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986; 110: 34-41. (Pubitemid 16011808)
11. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P,. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 2000; 31: 1507-1511.
12. Opitz O, Pietsch K, Ehlers S, Jacobs E,. Cytokine gene expression in immune mice reinfected with Mycoplasma pneumoniae: the role of T cell subsets in aggravating the inflammatory response. Immunobiology 1996-1997; 196: 575-587.
13. Lee KY,. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008; 6: 509-521.
14. Yang J, Hooper WC, Phillips DJ, Talkington DF,. Cytokines in Mycoplasma pneumoniae infections. Cytokines Growth Factor Rev 2004; 15: 157-168. (Pubitemid 38521251)
15. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD,. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. Infect Dis 2008; 198: 1180-1188.
16. Jick S,. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997; 16: 130-133.
17. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E,. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J 2011; 30 (2): e29-e37.
18. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, Yamaguchi T, Ouchi K, Oka M,. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 2011; 17 (1): 114-118.